The Learning Portal will be under maintenance Saturday, 8 August between 6 AM and 6 PM EST. Portal functionality will be unavailable during this window.
We apologize for any inconvenience caused during this time.

RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

 
Regulatory Focus™ > News Articles > 2020 > 7 > House spending bill would give FDA drug recall authority

House spending bill would give FDA drug recall authority

Posted 10 July 2020 | By Kari Oakes 

House spending bill would give FDA drug recall authority

The US House Committee on Appropriations approved a $3.212 billion budget for the Food and Drug Administration (FDA) on a voice vote Thursday. The budgeted amount is part of the fiscal year 2021 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies bill, which moved out of the Appropriations Committee on a voice vote.
 
The bill will now be placed on the calendar for consideration by the full House of Representatives. (RELATED: House proposes $3.2 billion for FDA in FY 2021, Regulatory Focus, 07 July 2020)
 
According to a press release from the Appropriations Committee, the bill now carries an amendment that would “give FDA legal authority to require the recall of unsafe prescription and over-the-counter drugs.”
 
The proposed 2021 budget for the FDA includes $70 million earmarked for medical product development acceleration, as provided by the 21st Century Cures Act, along with other boosts in medical product and food safety activities. Influenza vaccine manufacturing technology is also slated to receive additional funding under the proposed budget.
 
The budget would also allocate additional monies to the FDA for developing a regulatory framework for cannabidiol products, to have speedier responses to foodborne illness outbreaks, and to increase the safety and cybersecurity of medical devices.
 
In response to the COVID-19 pandemic, the proposed budget would add $31 million to help the agency review therapies and – potentially – vaccines to address the novel coronavirus.
 
 

Tags: FDA, US

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe